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Abstract
Background: Neuroleukin (NLK) is a protein with neurotrophic properties and is present in a proportion of senile
plaques and amyloid laden vessels. It has been suggested that NLK is part of a neuroprotective response to amyloid
β-induced cell death. The aim of our study was to investigate the value of cerebrospinal fluid (CSF) NLK levels as a
biomarker of vascular amyloid deposition in patients with cerebral amyloid angiopathy (CAA) and in patients with
amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD).
Methods: CSF NLK levels were quantified by ELISA in CAA patients (n = 25) and controls (n = 27) and in two
independent samples of aMCI patients, AD patients, and controls: (1) From the Radboud University Medical Center
(Nijmegen), we included n = 19 aMCI patients, n = 40 AD patients, and n = 32 controls. (2) From the Hospital of
Sant Pau (Barcelona), we included n = 33 aMCI patients, n = 17 AD patients, and n = 50 controls.
Results: CSF NLK levels were similar in CAA patients and controls (p = 0.95). However, we found an elevated CSF
concentration of NLK in aMCI (p < 0.0001) and AD patients (p < 0.0001) compared to controls in both samples sets.
In addition, we found a correlation of CSF NLK with CSF YKL-40 (age-adjusted-spearman-rank-coefficient = 0.82,
p < 0.0001) in aMCI/AD patients, a well-known glial marker of neuro-inflammation.
Conclusions: We found that CSF NLK levels are elevated in aMCI and AD patients compared to controls, but
are not increased in CAA patients. CSF NLK levels may be related to an increased neuroinflammatory state in
early stages of AD, given its association with YKL-40.
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Introduction
Alzheimer’s disease (AD) is the leading cause of demen-
tia worldwide. It is neuropathologically characterized by
the intracellular accumulation of hyperphosphorylated
tau protein in neurofibrillary tangles and by the extracel-
lular accumulation of amyloid-beta protein (Aβ). In AD,
Aβ is found in parenchymal senile plaques, and in many
cases also in the cerebral vasculature, referred to as cere-
bral amyloid angiopathy (CAA) [1]. The clinical diagno-
sis of AD is based on a gradual decline of cognition,
most commonly with an impairment in encoding and re-
call of recently learned information as well as evidence
of cognitive dysfunction in at least one other cognitive
domain [2]. Mild cognitive impairment (MCI) refers to
an early, but abnormal state of cognitive impairment
defined by memory complaints, objective memory
impairment, essentially preserved general cognitive
function, largely intact functional activities, but not de-
mented [3]. Cerebrospinal fluid (CSF) and neuroimaging
biomarkers can be used to support the diagnosis [4] and
have been proposed to define a prodromal stage of AD
based on the presence of MCI and evidence for amyloid
deposition (A), tau accumulation (T), and neurodegener-
ation (N) [4]. Beyond their supporting role in the
diagnosis, biomarkers may contribute to predicting
prognosis and may facilitate monitoring of disease
progression and treatment response. Furthermore, novel
biomarkers may advance our comprehension of the
different aspects of AD pathophysiology next to tau and
amyloid pathology.
CAA is the most prevalent co-pathology of AD, with
almost 80% of the patients having some degree of CAA
[5], likely because Aβ deposition is a shared feature of
senile plaques and CAA [6]. Vascular Aβ depositions
can also occur in the absence of AD and is recognized
as a designated type of cerebral small vessel disease, re-
ferred to as sporadic CAA. Sporadic CAA is associated
with cerebral (micro) hemorrhages and can also result in
a decline in cognitive function [5]. Sporadic CAA is
diagnosed during life using the MRI-based modified
Boston criteria [7], which rely on the hemorrhagic
manifestations of CAA. However, these are indirect signs
of relatively late-stage manifestations of CAA and they
do not provide definite proof of the disease.
Neuroleukin (NLK) may serve as biomarker for CAA or
AD. In an immunohistochemical study in AD patients,
NLK expression was found in senile plaques and in Aβ-
laden vessels [8]. In addition, messenger RNA levels of
NLK were increased in cultured human brain pericytes
after exposure to Aβ40 [8], which may represent an at-
tempt to survive Aβ-induced cell death. Furthermore, it
was shown that NLK can serve as a neurotrophic growth
factor [9] and may support survival of sensory and spinal
neurons and stimulate axonal growth [10–13].
CSF YKL-40 (also known as chitinase-3 like-protein 1
or cartilage glycoprotein-39) is an established neuroin-
flammatory marker [14]. YKL-40 is mainly expressed by
astrocytes, but also by microglia, often in close vicinity
to senile plaques and neurofibrillary tangles [15–17]. In-
creased CSF YKL-40 levels have been reported in cogni-
tively healthy APOE-ε4 carriers, amnestic mild cognitive
impairment (aMCI), and AD patients [14] and also in
frontotemporal dementia [18] and amyotrophic lateral
sclerosis [19].
The aim of our study was to examine CSF NLK levels
in patients with CAA and in two independent samples
of patients with aMCI or AD diagnosed according to
clinical criteria. We also studied the association of CSF
NLK in aMCI and AD patients with a positive biomarker
status A+T+(N+), and we performed an exploratory
study on the association of CSF NLK with CSF YKL-40,
and the known Alzheimer CSF biomarkers total tau,
phosphorylated tau, and Aβ42.
Methods
Participants
Sporadic CAA patients and controls
We included 14 patients with sporadic CAA from the
Massachusetts General Hospital (MGH), Boston, USA,
and 11 patients with sporadic CAA and 27 controls from
the Radboud University Medical Center, Nijmegen, the
Netherlands (RUMC). The inclusion criteria for the
CAA patients were a diagnosis of probable or definite
CAA according to the modified Boston criteria [7].
MMSE scores were available for a subset (n = 15) of
these patients (Table 1). Controls underwent a lumbar
puncture as part of the diagnostic workup of neurologic
symptoms or to exclude central nervous system involve-
ment of a systemic disease at the RUMC. They neither had
the suspected neurological disease nor a neurodegenerative
Table 1 Characteristics of the sporadic CAA patients and
controls
CAA (n = 25) Controls (n = 27) p-value
Age (years) 66 ± 10 63 ± 10 p = 0.32a
Sex, M/F (n) 13/12 12/15 p = 0.59b
MMSE score 28 [26–29]d N.A. -
TP (mg/ml) 0.91 [0.85–0.96] 0.83 [0.78–1.03] p = 0.12c
Aβ40 (pg/ml) 3745 [2200–4694] 6312 [4888–7381] p < 0.0001c
NLK (ng/ml) 3.39 [2.94–4.15] 3.31 [2.41–5.40] p = 0.95c
Values are medians and [IQR] except for age (mean ± SD) and sex (n). TP, NLK,
and Aβ40 were measured in CSF
Abbreviations: Aβ40 amyloid beta-40, CAA cerebral amyloid angiopathy, F
female, IQR interquartile range, M male, MMSE Mini-Mental State Examination,
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disease, known cognitive impairment, sepsis, a recent stroke
(< 6months), or a malignancy in the central nervous
system.
aMCI and AD patients and controls
We included two independent samples of patients with
amnestic mild cognitive impairment (aMCI), patients
with AD, and controls: we performed an initial analysis
including participants from the RUMC (the “Nijmegen
aMCI/AD patients and controls”) and a confirmatory
analysis in participants from the Memory Unit at
Hospital Sant Pau, Barcelona (the “Barcelona aMCI/AD
patients and controls”).
Nijmegen aMCI/AD patients and controls We in-
cluded 19 patients with aMCI, 40 patients with probable
AD, and 32 controls (different than the above-
mentioned n = 27), all from the RUMC. The inclusion
criteria were either a clinical diagnosis of aMCI accord-
ing to the Petersen criteria [3] at the moment of the
lumbar puncture followed by a diagnosis of probable AD
according to NINCDS-ADRDA criteria [20] in a later
stage, or a diagnosis of probable AD according to the
same criteria. Diagnoses were established during multi-
disciplinary memory clinic meetings. We used prede-
fined local cutoff values of CSF analysis to stratify the
patients and controls for their “ATN status” (Aβ42 (A+),
< 500 pg/ml; phosphorylated tau (T+), > 85 pg/ml; total
tau (N+), > 350 pg/ml) [21]. Mini Mental State Examin-
ation (MMSE) scores [22] were available for all aMCI and
AD patients (Table 2). These patients were compared with
32 controls from RUMC, fulfilling the criteria as men-
tioned above (“ Sporadic CAA patients and controls”).
Barcelona aMCI/patients and controls For validation
of our findings, we included 33 patients with aMCI, 17
patients with probable AD, and 50 cognitively normal
controls from the SPIN cohort (Memory Unit at
Hospital Sant Pau, Barcelona). Inclusion criteria were a
diagnosis of aMCI according to the Petersen criteria [3]
or probable AD according to the NINCDS-ADRDA cri-
teria [20]. Controls were spouses or children of patients,
and inclusion criteria were the absence of memory com-
plaints or significant impairment in other domains or
daily living activities, a clinical dementia rating global
score of 0, an MMSE score of > 27, and a Free and Cued
Selective Reminding Test (FCSRT) total immediate score
within normal range for age and education [23]. Mini
Mental State Examination (MMSE) scores [22] were avail-
able for all aMCI, AD patients, and controls (Table 2).
We used previously published local cutoff values to
stratify the patients and controls for their “ATN status”
(Aβ42 (A+), < 916 pg/ml; phosphorylated tau (T+), > 63
pg/ml; total tau (N+), > 456 pg/ml) [24].
CSF analysis
All participants in this study underwent a lumbar
puncture according to state-of-the-art local protocols.
At all locations, the CSF was collected in polypropylene
tubes, centrifuged, aliquoted, and stored in polypropyl-
ene tubes at − 80 °C. For all CSF analyses, the technician
who performed the analysis was blinded for the clinical
Table 2 Characteristics of Nijmegen aMCI/AD patients and controls
aMCI (n = 19) AD (n = 40) Controls (n = 32) p-value
Age (years) 72 [70–78] 74 [65–77] 61 [56–67] p < 0.0001a
Sex, M/F (n) 7/12 11/29 15/17 p = 0.24b
MMSE score 26 [23–27] 20 [17–24] N.A. p < 0.0001a
APOE genotype ε4+: n = 10
ε4−: n = 3
N.A.: n = 6
ε4+: n = 0
ε4−: n = 8
N.A.: n = 2
N.A. p = 0.58b
TP (mg/ml) 0.87 [0.79–0.93] 0.85 [0.76–0.96] 0.91 [0.79–.02] p = 0.51a
T-tau (pg/ml) 504 [419–691] 627 [321–956] 267 [179–386] p < 0.0001a
P-tau (pg/ml) 91.0 [71.0–114.0] 97.5 [79–129] 47.5 [32.3–56.8] p < 0.0001a
Aβ42 (pg/ml) 459 [404-516] 468 [389–564] 864 [664–1142] p < 0.0001a
NLK (ng/ml) 4.66 ± 1.40 4.84 ± 1.58 3.07 ± 1.2 p < 0.0001d
GCA score n = 7; 2 [2–2] n = 28; 1.5 [1–2] n = 4; 0.5 [0–1] p = 0.006c
Mean MTA n = 5; 1.5 [1–2.25] n = 28; 1 [1–2] n = 2; 0 [0–0] p = 0.125c
Medians and [IQR] are reported for all characteristics and markers, except for NLK (mean ± SD) and sex (n). T-tau, P-tau, Aβ42, and NLK were measured in CSF
Abbreviations: AD Alzheimer’s disease, Aβ42 amyloid beta-42, APOE Apolipoprotein E, aMCI amnestic mild cognitive impairment, F female, GCA global cortical
atrophy, IQR interquartile range, M male, MMSE Mini-Mental State Examination, MTA medial temporal lobe atrophy, N.A. not available, NLK neuroleukin, P-tau
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diagnoses, and patient and controls samples were ran-
domly analyzed to overcome bias.
NLK was quantified in CSF using the human glucose-
6-phosphate isomerase ELISA kit (cat no. Ab171575;
Abcam, Cambridge, UK) according to the manufac-
turers’ instructions [25]. A standard curve ranging from
156 to 10,000 pg/ml was constructed using serial two-
fold dilutions. CSF samples were diluted six times prior
to analysis.
Total protein levels in CSF were determined using
PierceTM BCA protein assay kit (Thermo Fisher Scien-
tific, Waltham, MA, USA). In all NLK and total protein
CSF analyses, five quality controls were included on each
plate in each test run to correct for any inconsistencies
between plates. These controls consisted of pooled CSF
samples that were stored in aliquots at −80 °C. For each
analysis, a fresh aliquot was used.
Aβ42, tau phosphorylated at threonine 181 (p-tau),
and total tau (t-tau) levels in CSF of Nijmegen aMCI/
AD patients and controls were analyzed using Innotest
ELISAs (Fujirebio, Gent, Belgium). Test characteristics
of these assays have been described previously [26]. In
Barcelona aMCI/AD patients and their controls, these
biomarkers were analyzed using automated versions of
the same assays using a Lumipulse apparatus (Fujirebio,
Gent, Belgium).
Aβ40 levels in CSF of CAA patients and their controls
were analyzed using an ELISA (Euroimmun, Lübeck,
Germany). APOE genotyping was performed as described
earlier [27].
CSF YKL-40 measurements were available for a subset
(n = 29 controls, n = 13 aMCI, n = 5 AD patients) of the
Barcelona patients and controls. These were analyzed
as described earlier (MicroVueTM, Quidel, San Diego,
CA) [28].
MRI acquisition and analysis
MRIs were obtained in a clinical setting, and field
strength was either 1.5 or 3.0 T. MRI analysis included
axial and coronal T1-weighted and T2-weighted se-
quences. MRI images were reviewed blinded to all clin-
ical and CSF data and scored for medial temporal lobe
atrophy (MTA) [29] and global cortical atrophy (GCA)
[30]. The MTA scale assesses the width of the choroidal
fissure and the temporal horn, and the height of the hip-
pocampal formation on a 5-grade rating scale [29]. Both
hemispheres were scored, and the mean score of the left
and right hemisphere was used. The GCA score is the
mean score for cortical atrophy throughout the entire
cerebrum and was rated by a 4-point scale [30]. Each
MRI was rated independently by two trained raters (AK
and LR), and there was a good agreement between the
two raters: a weighted Cohen’s κ of 0.69 for GCA and
0.73 for MTA. In case of a disagreement, consensus was
reached by consultation of a skilled vascular geriatrician
(JC).
Data analysis
We used the software programs IBM SPSS statistics for
Windows, version 25.0 (Armonk, NY: IBM Corp) and
GraphPad Prism 5.03 (La Jolla, CA). If parameters had a
Gaussian distribution, parameters were depicted as mean
± standard deviation and group differences were ana-
lyzed with a Student’s t-test or an ANOVA. Otherwise,
parameters were stated as medians with interquartile
ranges and differences were analyzed with a Mann-
Whitney U test or a Kruskal-Wallis test. The Shapiro-
Wilk test was used to analyze the normality of the data.
Sex frequency was analyzed by a chi-square test. GCA
and MTA were compared using Fisher’s exact test.
When comparing group differences of NLK levels, we
adjusted for age and sex by performing multiple regres-
sion analysis with patient group, age and sex as inde-
pendent variables. In a second model, we adjusted for
age, sex, and CSF total protein levels. To explore poten-
tial specific relationships between NLK and Alzheimer
pathology, we performed a subgroup analysis of aMCI/
AD patients who were “AD biomarker positive” (i.e., A+
T+(N+)) compared with “AD biomarker-negative” (i.e.,
A−T−(N−)) controls. We pooled aMCI and AD bio-
marker positive individuals to increase the power of this
analysis. To determine the diagnostic accuracy of NLK
for the distinction between aMCI patients and controls,
and between AD patients and controls, we determined
the area under the curve (AUC) using a receiver operat-
ing characteristic curve (ROC) with 95% confidence
interval (CI). Spearman rank correlation (rSP) was used
to evaluate correlation between age, total protein, and
MMSE score with NLK. We used partial correlation with
age as a covariate to adjust for age when investigating
the association between t-tau, p-tau, Aβ42, YKL-40,
GCA, MTA, and NLK. To further explore the associ-
ation of NLK with YKL-40, we also performed this
analysis in the controls and the MCI/AD patients
separately.
Ethical statement
Lumbar punctures and vena punctures were performed
after informed consent from the patients themselves or
from the patients’ legal representatives. The CSF of AD
patients, controls, and the majority of the CAA patients
from the RUMC (n = 7) originated from a clinical diag-
nostic work-up. Four CAA patients underwent a lumbar
puncture in the context of a cohort study on biomarkers
for CAA (CAVIA; no. 733050202). This study was
approved by the Medical Ethics Committee Arnhem-
Nijmegen (file nos. 2016-3011 and 2014-1401), Ethical
Committee of IIB-Sant Pau (16/2013), and Partners
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Human Research Committee of Boston (study ID PHRC
#2006P000664).
Results
NLK assay for quantification in CSF
The lower limit of detection (LLOD) of the NLK ELISA
was 61 pg/ml. All CSF measures were above the LLOD.
The mean intra-assay coefficient of variation (CV) for CSF
samples (duplicate measures) was 3.6 ± 3.6% and the
mean inter-assay CV was 4.9 ± 2.9%. The variation be-
tween the ELISA plates, based on quality control measure-
ments, ranged from a factor 0.89 to 1.08, for which the
CSF measures were corrected accordingly, by recalculating
the results using the results of one plate as a reference.
CSF NLK levels in sporadic CAA patients and controls
Age and sex distribution of the CAA patients (age 66 ±
10 years, 52% male) and controls (age 63 ± 10 years, 44%
male) was similar (Table 1). Patients were assigned to
the following categories of certainty: definite CAA (aut-
opsy confirmed, n = 2), probable CAA with supporting
pathology (n = 6), and probable CAA (n = 17). CSF NLK
levels, adjusted for age and sex, were similar (p = 0.40,
see Table 1 and Fig. 1A) in CAA patients and controls.
Additional adjustment for CSF total protein did not
affect the results (p = 0.34).
We observed an increase in CSF NLK with increasing age
(rSP = 0.37, p = 0.014), but we found no correlation with
total protein (rSP = 0.008, p = 0.95). Furthermore, CSF NLK
correlated with MMSE score (rSP = −0.76, p = 0.001).
CSF NLK levels in Nijmegen aMCI/AD patients and
controls
Sex distribution was similar, whereas aMCI (median age
72 [70–78] years, 37% male) and AD patients (median
age 74 [65–77] years, 28% male) were older (both p <
0.0001) than the control subjects (median age 61 [56–
67] years, 47% male; Table 2). CSF NLK levels were,
adjusted for age and sex, increased in aMCI patients
compared to controls (p = 0.009; Table 2 and Fig. 1B)
and in AD patients compared to controls (p < 0.0001).
Additional adjustment for CSF total protein did not
affect the results (p = 0.005 and p < 0.0001,
respectively).
Furthermore, in n = 28 aMCI/AD patients with
positive AD biomarkers (A+T+(N+)) the mean CSF
NLK concentration (5.21 ± 1.08 ng/ml) was higher than
in n = 20 controls with normal AD biomarker status (A
−T−(N−); 2.72 ± 1.0 ng/ml; when adjusted for age and
sex (p < 0.0001; Fig. 1C), and after additional adjustment
for total protein (p < 0.0001).
CSF NLK significantly correlated with age (rSP = 0.39,
p < 0.0001) and with CSF total protein levels (rSP = 0.22,
p = 0.039).
CSF NLK levels in Barcelona aMCI/AD patients and
controls
Sex distribution was similar, whereas aMCI (mean age
70 ± 3 year, 30% male), and AD patients (mean age 67 ±
7 years, 47% male) were older (p < 0.0001 and p = 0.002)
than the control subjects (mean age 63 ± 4 years, 50%
male; Table 3). When adjusted for age and sex, there
was a significant difference between aMCI patients and
controls (p = 0.018; Table 3 and Fig. 1D), and between
AD patients and controls (p = 0.008). Additional adjust-
ment for CSF total protein yielded similar results (p =
0.013 and p = 0.005, respectively).
We found a higher mean CSF NLK (4.44 ± 1.28 ng/
ml) in n = 40 aMCI/AD patients with positive AD
biomarkers (A+T+(N+)) than in n = 41 controls with
normal AD biomarker status (A−T−(N−), 3.15 ± 0.91
ng/ml, p = 0.001; Fig. 1E), when adjusted for age and
sex. This difference remained after additional adjustment
for total protein (p = 0.001).
Again, NLK correlated with age (rSP = 0.43, p < 0.0001)
and with total protein (rSP = 0.32, p < 0.0001).
ROC analysis
We found an AUC of 0.81 (95% CI 0.68–0.93; Fig. 2A)
to discriminate aMCI patients from controls in the
Nijmegen sample, and an AUC of 0.74 (95% CI 0.63–
0.85) in the Barcelona sample.
We found an AUC of 0.82 (95% CI 0.73–0.92; Fig. 2B)
to discriminate AD patients from controls in the
Nijmegen sample, and an AUC of 0.83 (95% CI 0.73–
0.93) in the Barcelona sample.
Correlation of CSF NLK with other CSF biomarkers and
MRI markers
CSF NLK correlated with CSF YKL-40 (Spearman rank
coefficient, adjusted for age (rSPc) = 0.34, p < 0.019) in
the combined Barcelona aMCI/AD patients and controls
(Fig. 3). This correlation was prominent in the aMCI/
AD patients (rSPc = 0.82, p < 0.0001), but not in the con-
trols (rSPc = −0.14, p = 0.47).
CSF NLK levels correlated with CSF t-tau levels
(Nijmegen aMCI/AD patients and controls: rSPc = 0.65,
p < 0.0001; Barcelona aMCI/AD patients and controls
rSPc = 0.60, p < 0.0001) and CSF p-tau levels (Nijmegen
aMCI/AD patients and controls: rSPc = 0.65, p < 0.0001;
Barcelona aMCI/AD patients and controls: rSPc = 0.58, p
< 0.0001). CSF NLK correlated with Aβ42 levels in the
Nijmegen aMCI/AD patients and controls (rSPc = −0.29,
p = 0.005), but not in the Barcelona aMCI/AD patients
and controls (rSPc = −0.014, p = 0.89).
There was neither a correlation between CSF NLK and
GCA score (rSPc = 0.23, p = 0.17), nor with mean MTA
score (rSPc = −0.036, p = 0.84).
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Discussion
The main findings of our study are as follows: (1) CSF
NLK levels were increased in aMCI patients and in AD
patients, as established in two independent samples from
two different centers. (2) The increase in CSF NLK was
particularly strong in “AD biomarker positive A+T+(N+
)” aMCI and AD patients compared to A−T−(N−)
controls. (3) CSF NLK levels were associated with CSF
YKL-40 levels in aMCI/AD patients, which suggests an
association of NLK with neuroinflammation. (4) CSF
NLK levels were not increased in sporadic CAA patients
versus controls.
Fig. 1 CSF NLK levels in the sporadic CAA patients and controls (A) and in the aMCI/AD patients and controls (B–E), with and without
stratification for AT(N) status. Box and scatterplots in all panels (depicting median, interquartile range and range). A NLK levels in CAA patients
and controls. The NLK levels were similar (p = 0.95). B CSF NLK levels in aMCI patients, AD patients, and controls from Nijmegen. These levels
were increased in aMCI (p = 0.001) and AD patients (p < 0.0001) compared to controls. C NLK levels in A+T+(N+) aMCI/AD patients and A−T−(N
−) controls from Nijmegen. NLK levels were significantly higher in A+T+(N+) aMCI/AD patients (p < 0.0001). D CSF NLK levels in aMCI patients,
AD patients, and controls from Barcelona. Levels were significantly higher in aMCI patients (p < 0.0001) and AD patients (p < 0.0001) compared to
controls. E NLK levels in A+T+(N+) aMCI/AD patients and A−T−(N−) controls from Barcelona. NLK levels were significantly higher in A+T+(N+)
aMCI/AD patients (p < 0.0001). Abbreviations: AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fluid; aMCI, amnestic
mild cognitive impairment; ns, non-significant. **p < 0.01, ***p < 0.001
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NLK is a 56-kDa multifunctional protein named after
two of its functions: it can act as a neurotrophic factor
and as a lymphokine [12]. In the extracellular space
NLK supports neuronal survival and stimulates axonal
growth [10–13], but NLK may also play a role in the in-
duction of B-cell differentiation into antibody-secreting
cells [9]. NLK is also known as glucose-6-phosphate
isomerase or phosphohexose isomerase, an intracellular
enzyme involved in glycolysis and gluconeogenesis [31],
as autocrine motility factor, a tumor maturation factor
in cancer cells, playing a role in metastasis [32] and as a
maturation factor, mediating differentiation of human
myeloid leukemia cells [33]. In an immunohistochemical
study in AD patients, NLK expression was found in neu-
rons, microglia, and oligodendroglia, and in the vessel
wall, specifically in cerebrovascular cells such as smooth
muscle cells [8]. NLK has also been investigated in the
context of other neurodegenerative diseases: in a trans-
genic mouse model of Huntington’s disease, the NLK
gene was upregulated [34]. Furthermore, in patients with








Age (years) 70 ± 3 67 ± 7 63 ± 4 p < 0.0001a
Sex, M/F (n) 10/23 8/9 25/25 p = 0.20b
MMSE score 26 [25–28] 20 [19–25] 29 [29–30] p < 0.000d
APOE genotype ε4+: n = 24
ε4−: n = 8
N.A.: n = 1
ε4+: n = 6
ε4−: n = 10
N.A.: n = 1
ε4+: n = 10
ε4−: n = 38
N.A.: n = 2
p < 0.0001c
TP (mg/ml) 0.78 [0.72–0.88] 0.79 [0.71–0.88] 0.78 [0.69–1.04] p = 0.99d
T-tau (pg/ml) 647 [411–823] n = 15; 742 [598–1163] 265.0 [227–305] p < 0.0001d
P-tau (pg/ml) 101.3 [78.0–143.8] 114.1 [79.9–147.6] 40.0 [29.3–47.8] p < 0.0001d
Aβ42 (pg/ml) 511 [421–623] 420 [372–575] 1240 [1036–1600] p < 0.0001d
NLK (ng/ml) 3.88 [3.00–5.24] 4.17 [3.61–4.60] 2.82 [2.30–3.60] p < 0.0001d
YKL-40 (ng/ml) n = 13; 324 ± 63 n = 5; 323 ± 40 n = 29; 226 ± 51 p < 0.0001a
Characteristics of the Barcelona AD-control group. Medians and [IQR] are reported, except for age and YKL-40 (mean ± SD), and sex (n). TP, T-tau, P-tau, Aβ42, NLK
and YKL-40 were measured in CSF
Abbreviations: AD Alzheimer’s disease, Aβ42 amyloid beta-42, APOE Apolipoprotein E, aMCI amnestic mild cognitive impairment, F female, IQR interquartile range,
M male, MMSE Mini-Mental State Examination, N.A. not available, NLK neuroleukin, P-tau phosphorylated tau, SD standard deviation, TP total protein, T-tau total
tau, YKL-40 protein associated with neuro-inflammation and Alzheimer’s disease, named after the first three N-terminal amino acids: tyrosine (Y), lysine (K), and





Fig. 2 A ROC analysis showed moderately high accuracy levels for discrimination of aMCI from control in the Nijmegen aMCI patients and
controls (gray line) and the Barcelona aMCI patients and controls. B ROC analysis showed consistently high accuracy levels for discrimination of
AD from control in the Nijmegen AD patients and controls (gray line) and the Barcelona AD patients and controls. Abbreviations: AD, Alzheimer’s
disease; AUC area under the curve. The Barcelona cohort serves as a validation cohort
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Parkinson’s disease and multiple system atrophy, CSF
NLK levels were normal [25].
Our finding that CSF NLK is increased in aMCI pa-
tients suggests that altered levels are already present in
prodromal AD, and that NLK might serve as an early
biomarker for AD. Levels were also altered in AD pa-
tients. We found similar effects sizes and AUC’s of CSF
NLK in aMCI patients and AD patients in two inde-
pendent samples of patients and controls, indicating that
our results are consistent. However, there is overlap of
NLK levels between aMCI patients and controls. More
studies will be needed to confirm this association of
NLK with different stages of AD as well as its potential
biomarker value for early diagnosis.
We observed a marked increase of NLK in aMCI/AD
with a positive AD biomarker status, and a clear correl-
ation with CSF p-tau and t-tau, whereas we found no or
only a weak correlation of NLK with CSF Aβ42. To-
gether, these findings suggest that an increased cerebral
NLK production is tightly associated with tau-mediated
neurodegeneration.
In line with this, we found that CSF NLK strongly cor-
related with CSF YKL-40 (also known as chitinase-3
like-protein 1 or cartilage glycoprotein-39), an estab-
lished neuroinflammatory marker [14], expressed by
astrocytes and microglia. Furthermore, our finding that
this association is very strong in the aMCI/AD group
suggests that a neuroinflammatory process involving in-
creased production of NLK and YKL-40 may be particu-
larly associated with the early phases of the disease
process.
Chronic microglial inflammation has been observed in
the brains of AD patients at various disease stages, and
pro-inflammatory cytokines such as IL-1β, IL-2, IL-6,
and tumor necrosis factor-α have been shown to be
upregulated in AD [35]. In addition, genome-wide asso-
ciation studies have identified associations between in-
flammation- and immune-related variants in genes (such
as a missense mutation in the gene encoding for
TREM2, a receptor expressed on microglia) and in-
creased AD risk [36]. Furthermore, Aβ may initiate
microglial activation, resulting in microglial migration to
plaques, phagocytosis, and enzymatic degradation of Aβ
[37]. Prolonged microglial activation may be detrimental,
since it eventually leads to a self-perpetuating cycle in-
volving the production of neurotoxic pro-inflammatory
cytokines, damaging neurons, inducing more recruit-
ment of microglia, further increasing their activation and
release of pro-inflammatory cytokines [35].
Inflammation does, however, not seem to be a major
component in CAA-related microhemorrhage or
microinfarction [38], with the exception of a rare
clinical subtype: CAA-related inflammation [6]. On
the other hand, previous immunohistochemical stud-
ies in AD patients and in a transgenic rat model of
CAA have found that CAA type 1, i.e., amyloid de-
position in the capillary vessels, was associated with
perivascular inflammation [39, 40].
We previously demonstrated by immunohistochemis-
try that NLK may be associated with CAA pathology [8],
but apparently this association is not reflected by an in-
crease of NLK in the CSF. We could speculate that CAA
pathology, in contrast to AD pathology, does not lead to
a neuroprotective response involving NLK to an extent
in which that is reflected by an increase of NLK in the
CSF. The correlation between NLK and MMSE levels
might suggest that NLK levels in CAA patients are influ-
enced by cognition (and possibly additional AD path-
ology). However, since we only have the availability of
MMSE scores in a subset of CAA patients, we should in-
terpret these data with caution.
Strengths and limitations
A limitation of this study is that we did not have
YKL-40 levels available for the Nijmegen CAA, AD
patients, and controls. However, the correlation in
the Barcelona samples is quite strong. In addition,
the lack of detailed information on the cognitive
status of CAA patients obstructed us from systemat-
ically analyzing this as a possible confounding factor
for the analysis of NLK levels. Furthermore, controls
were significantly younger than the aMCI patients
and AD patients. However, when we adjusted for
age, difference between patients and controls
remained significant. Our group sizes were relative
small, but a strength of our study is the inclusion of
aMCI/AD and controls subjects with thorough clin-
ical evaluation, for many of whom imaging and AD
Fig. 3 Scatter plot of the correlation between CSF NLK levels and
YKL-40 levels in a subset (n = 47) of the Barcelona aMCI/AD patients
and controls. NLK and YKL-40-levels significantly correlated in the
combined aMCI/AD and controls (rSP = 0.51, p < 0.0001, gray line)
and in the aMCI/AD patients separately (rSP = 0.79, p < 0.0001, black
dots and black line), but not in the controls (rSP = 0.033, p = 0.87,
white dots, dotted line). Abbreviations: AD, Alzheimer’s dementia; rSP,
Spearman rank coefficient; aMCI, amnestic mild cognitive
impairment; NLK, neuroleukin; YKL-40, chitinase-3 like-protein 1
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biomarker data was also available. Another important
strength is that we were able to validate our findings
in two independent aMCI/AD samples.
Conclusions
We conclude that CSF NLK is increased in aMCI and
AD patients, but not in CAA patients, which indicates
that it is a marker associated with early stage AD. NLK
is a neurotrophic factor, possibly involved in a neuropro-
tective response to neuronal damage caused by AD
pathology. The strong correlation of NLK with YKL-40
suggests an inflammatory role for NLK as well. Future
studies will have to confirm whether an increase in CSF
NLK is associated with early stages of AD and whether
NLK has an additive value as biomarker for the differen-
tial diagnosis of dementia syndromes.
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